A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery
- PMID: 17666531
- PMCID: PMC1941805
- DOI: 10.1073/pnas.0610292104
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery
Abstract
The U.S. National Cancer Institute has used a panel of 60 diverse human cancer cell lines (the NCI-60) to screen >100,000 chemical compounds for anticancer activity. However, not all important cancer types are included in the panel, nor are drug responses of the panel predictive of clinical efficacy in patients. We asked, therefore, whether it would be possible to extrapolate from that rich database (or analogous ones from other drug screens) to predict activity in cell types not included or, for that matter, clinical responses in patients with tumors. We address that challenge by developing and applying an algorithm we term "coexpression extrapolation" (COXEN). COXEN uses expression microarray data as a Rosetta Stone for translating from drug activities in the NCI-60 to drug activities in any other cell panel or set of clinical tumors. Here, we show that COXEN can accurately predict drug sensitivity of bladder cancer cell lines and clinical responses of breast cancer patients treated with commonly used chemotherapeutic drugs. Furthermore, we used COXEN for in silico screening of 45,545 compounds and identify an agent with activity against human bladder cancer.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Fig. 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1941805/bin/zpq0200763200001.gif)
![Fig. 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1941805/bin/zpq0200763200002.gif)
![Fig. 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1941805/bin/zpq0200763200003.gif)
Similar articles
-
Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy.Assay Drug Dev Technol. 2015 Dec;13(10):623-7. doi: 10.1089/adt.2015.29012.dlgdrrr. Assay Drug Dev Technol. 2015. PMID: 26690765 Free PMC article.
-
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.Bioorg Med Chem. 2012 Mar 15;20(6):1947-51. doi: 10.1016/j.bmc.2012.01.017. Epub 2012 Jan 21. Bioorg Med Chem. 2012. PMID: 22336246 Review.
-
The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.Cancer Res. 2010 Mar 1;70(5):1753-8. doi: 10.1158/0008-5472.CAN-09-3562. Epub 2010 Feb 16. Cancer Res. 2010. PMID: 20160033 Free PMC article. Review.
-
Predicting cancer drug response by proteomic profiling.Clin Cancer Res. 2006 Aug 1;12(15):4583-9. doi: 10.1158/1078-0432.CCR-06-0290. Clin Cancer Res. 2006. PMID: 16899605
-
Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics.Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S74-9. doi: 10.1007/s00280-003-0649-1. Epub 2003 Jun 18. Cancer Chemother Pharmacol. 2003. PMID: 12819939 Review.
Cited by
-
Biomarker challenges in the pursuit of personalized neoadjuvant chemotherapy for muscle-invasive bladder cancer: conclusions from SWOG S1314.Transl Androl Urol. 2024 Mar 31;13(3):458-462. doi: 10.21037/tau-23-620. Epub 2024 Mar 12. Transl Androl Urol. 2024. PMID: 38590957 Free PMC article. No abstract available.
-
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.Clin Cancer Res. 2024 Jan 17;30(2):444-449. doi: 10.1158/1078-0432.CCR-23-0602. Clin Cancer Res. 2024. PMID: 37966367 Clinical Trial.
-
Bioinformatics in urology - molecular characterization of pathophysiology and response to treatment.Nat Rev Urol. 2024 Apr;21(4):214-242. doi: 10.1038/s41585-023-00805-3. Epub 2023 Aug 21. Nat Rev Urol. 2024. PMID: 37604982 Review.
-
MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas.Nat Commun. 2023 Jul 27;14(1):4533. doi: 10.1038/s41467-023-40235-8. Nat Commun. 2023. PMID: 37500667 Free PMC article.
-
A noval prognostic signature of the N7-methylguanosine (m7G)-related miRNA in lung adenocarcinoma.BMC Pulm Med. 2023 Jan 12;23(1):14. doi: 10.1186/s12890-022-02290-7. BMC Pulm Med. 2023. PMID: 36635678 Free PMC article.
References
-
- Goodman MT, Hernandez BY, Hewitt S, Lynch CF, Cote TR, Frierson HF, Jr, Moskaluk CA, Killeen JL, Cozen W, Key CR, et al. Hum Pathol. 2005;36:812–820. - PubMed
-
- Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, Schultz PG, Powell SM, Moskaluk CA, Frierson HF, Jr, et al. Cancer Res. 2001;61:7388–7393. - PubMed
-
- Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, et al. Science. 1999;286:531–537. - PubMed
-
- Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, et al. Lancet. 2003;362:362–369. - PubMed
-
- Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. J Clin Oncol. 2006;24:778–789. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources